Highly pathogenic avian influenza (H5N1) is no longer just a poultry problem. Since its detection in U.S. dairy cattle in 2024, the virus has spread across herds, cutting milk production, driving economic losses and raising concerns about zoonotic transmission to humans. Infected cows can lose substantial milk output in a matter of weeks. The virus has been detected in milk, respiratory secretions and mammary tissue.
Despite this, there are currently no licensed influenza vaccines for cattle, leaving producers reliant on biosecurity and herd management to limit spread.
Against this backdrop, researchers at the University of Nebraska–Lincoln have developed a vaccine designed to keep pace with a virus that is both evolving and expanding its host range. Rather than targeting a single strain, the approach uses a centralized consensus H5 antigen, positioned near the center of the virus’s evolutionary tree to maximize cross-protection across variants.
Dual-Route Delivery Targets Where Infection Starts
What sets this vaccine apart is not just its breadth, but how it is delivered. Researchers combined intramuscular and intranasal administration, aiming to activate immune defenses both throughout the body and at the primary site of infection.
“The idea was that if we put it intramuscularly, we can prevent it from spreading in the body, and then a mucosal aspect, intranasally, would prevent it from spreading from animal to animal,” said Eric Weaver, professor of biological sciences and director of the Nebraska Center for Virology, in a news release.
This dual-route design is intended to generate:
- Systemic immunity through circulating antibodies and T cells
- Mucosal immunity in the respiratory tract, where influenza viruses first establish infection
Together, these responses may improve protection against disease while also reducing viral transmission.
The platform uses adenoviral vectors in a prime–boost regimen, switching vector types between doses to strengthen immune responses and avoid interference from preexisting immunity.
Strong and Broad Immune Responses
The vaccine was evaluated in both mice and Holstein dairy calves, with consistent findings across species. In each model, it generated robust immune responses spanning multiple arms of the immune system.
Antibodies isolated from animal serum and nasal swabs recognized a wide panel of H5 strains, from early isolates in the late 1990s through recent 2024 bovine strains. Mucosal IgA responses increased notably after booster vaccination, indicating the vaccine is effectively engaging respiratory immunity.
In parallel, strong T-cell responses were observed against both historical and contemporary viral strains, supporting the idea that protection may extend beyond traditional neutralizing antibody responses.
Complete Protection in Challenge Studies
In mouse challenge experiments, the vaccine demonstrated strong protective efficacy. Animals exposed to lethal doses of divergent H5N1 strains, including a recent bovine isolate, showed minimal clinical signs and survived infection.
- Vaccinated mice maintained body weight and showed no significant disease
- All unvaccinated controls experienced severe disease and were euthanized
This protection occurred even when neutralizing antibody responses were limited against some strains, suggesting broader immune mechanisms, including T cells, play a key role.
Still Early, but Promising
“We’d like to have a vaccine for the farm and the farmer, and everything shows that this would be an effective vaccine platform for humans as well,” Weaver said.
While the findings are encouraging, the vaccine remains in the experimental stage. The study did not include challenge trials in cattle, and questions remain about durability, field performance and effectiveness against fully virulent strains.
Even so, the results point to a meaningful shift in influenza vaccine design. By combining cross-reactive antigen targeting with dual-route delivery, this approach aims to anticipate viral evolution rather than react to it.
If those advantages hold up in real-world conditions, it could offer a much-needed tool for managing H5N1 in cattle and reducing the risk of further spillover.
